-
公开(公告)号：US10583156B2
公开(公告)日：2020-03-10
申请号：US15828971
申请日：2017-12-01
IPC分类号： C07K19/00 , A61K39/39 , A61K35/17 , C07K14/82 , A61K39/395 , C07K14/47 , C07K14/725 , C07K14/73 , C07K14/705 , C12N5/0783 , A61K38/00
摘要： This present disclosure relates to methods and compositions comprising biologically active nanoparticle formulations of MYC protein. Provided are methods of making the nanoparticle formulations and methods of using the nanoparticle formulations for treatment.
-
公开(公告)号：US20200030433A1
公开(公告)日：2020-01-30
申请号：US16562132
申请日：2019-09-05
申请人： Theraphage Inc.
摘要： Described herein is a fusion protein comprising a bacteriophage protein fused to a cancer antigen. Vaccines are also described, as well as methods of treatment and/or prevention of cancer and methods of immunizing an individual.
-
33.发明授权公开(公告)号：US10533041B2
公开(公告)日：2020-01-14
申请号：US16281790
申请日：2019-02-21
发明人： Andrea Mahr , Toni Weinschenk , Helen Hoerzer , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC分类号： A61K39/00 , C07K14/47 , C07K14/74 , C12N15/115 , C07K7/08 , C07K7/06 , C07K16/28 , C12N5/0783 , A61K35/17 , C07K16/30 , C12P21/02 , C12Q1/6881 , G01N33/569 , C07K14/82 , C07K16/32 , C12Q1/6886 , G01N33/574 , C07K14/705 , C07K16/18 , A61K38/00 , A61K35/12
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20190382468A1
公开(公告)日：2019-12-19
申请号：US16433438
申请日：2019-06-06
发明人： Laura Soucek , Marie-Eve Beaulieu
摘要： The invention relates to a Myc dominant negative mutant, called Omomyc, for use in medicine and for use in the prevention and/or treatment of cancer. The invention also refers to a fusion protein comprising Omomyc and pharmaceutical composition thereof and their use in medicine and, in particular, for treatment of cancer.
-
公开(公告)号：US20190314411A1
公开(公告)日：2019-10-17
申请号：US16387166
申请日：2019-04-17
发明人： Lei Xiao , Zhiyuan Cao , Chengfei Pu , He Sun
IPC分类号： A61K35/17 , C07K14/725 , C07K14/82 , C07K16/28 , C12N15/86 , A61K38/20 , A61K38/19 , A61P35/00
摘要： The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion and/or maintenance in vivo and/or in vitro. For example, a method of enhancing T cell-based therapy comprises administering genetically modified T cells comprising a first chimeric antigen receptor (CAR) and a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR binds a surface molecule or antigen of a white blood cell.
-
公开(公告)号：US10442853B2
公开(公告)日：2019-10-15
申请号：US15244138
申请日：2016-08-23
发明人： Yosef Refaeli , Brian Turner
IPC分类号： C07K14/82 , C12N5/10 , A61K35/17 , C07K16/00 , C07K16/10 , C07K16/40 , C12N15/113 , A61K39/00
摘要： Provided herein are various processes for the improved production of antibody producing organisms, antibody producing tissues, antibody producing cells and antibodies. In certain embodiments, provided herein are methods for rapidly producing antibody producing organisms, tissues, cells and antibodies derived from humans, organisms, plants or cells that are genetically altered to over-express certain proteins.
-
37.发明申请公开(公告)号：US20190249192A1
公开(公告)日：2019-08-15
申请号：US16390797
申请日：2019-04-22
申请人： RIKEN
发明人： Shin-ichiro Fujii
CPC分类号： C12N15/85 , A61K39/0011 , A61K39/001153 , A61K2039/5152 , A61K2039/5156 , C07K14/4748 , C07K14/82 , C07K2319/00 , C07K2319/50
摘要： A cell for immunotherapy of the present invention includes a nucleic acid encoding a Wilms tumor 1 gene product or a fragment of the Wilms tumor 1 gene product, wherein the nucleic acid including (i) a region encoding a fragment of the Wilms tumor 1 gene product, the fragment being indicated by positions 194 to 493 of amino acid sequence of SEQ ID NO:1 or by positions corresponding to the positions 194 to 493 of amino acid sequence corresponding to SEQ ID NO:1 and (ii) only one AUG as a functional start codon, connected to a 5′ terminal side of the region via 3m (m is 124-192) bases intervening between the AUG as the functional start codon and the 5′ terminal side of the region, and a nucleic acid encoding CD1d, wherein the cell has been loaded with a glycolipid recognized by antigen receptor of NKT cell.
-
公开(公告)号：US10370434B2
公开(公告)日：2019-08-06
申请号：US14889656
申请日：2014-05-07
发明人： Laura Soucek , Marie-Eve Beaulieu
摘要： The invention relates to a Myc dominant negative mutant, called Omomyc, for use in medicine and for use in the prevention and/or treatment of cancer. The invention also refers to a fusion protein comprising Omomyc and pharmaceutical composition thereof and their use in medicine and, in particular, for treatment of cancer.
-
公开(公告)号：US20190144946A1
公开(公告)日：2019-05-16
申请号：US15977810
申请日：2018-05-11
IPC分类号： C12Q1/6886 , C12Q1/48 , C07K14/82 , G01N33/574
摘要： The invention described herein relates to novel genes and their encoded proteins, termed Mutants Associated with Resistance to STI-571 (e.g., T315I Bcr-Abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express MARS. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of MARS.
-
40.发明申请公开(公告)号：US20190092824A1
公开(公告)日：2019-03-28
申请号：US16212178
申请日：2018-12-06
发明人： Andrea MAHR , Toni Weinschenk , Helen Hoerzer , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC分类号： C07K14/47 , G01N33/574 , C07K16/18 , C12P21/02 , C07K16/30 , A61K35/17 , C07K14/82 , C07K14/705 , C07K14/74 , A61K39/00 , C07K7/06 , C12N5/0783 , C12N15/115 , C07K7/08 , C07K16/28 , C12Q1/6886 , G01N33/569 , C07K16/32 , C12Q1/6881 , A61K38/00 , A61K35/12
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
-
-
-
-
-
-
-
-
搜索结果
1379 条记录 (耗时 0.05 秒)
